Inclusion Criteria:

- Any patient with marrow failure and increased chromosome fragility as determined in
the diepoxybutane (DEB) or mitomycin C test

- Any patient with FA with marrow failure meeting the following criteria:

- Granulocyte count < 0.2 x 10^9/L

- Platelet count < 20 x 10^9/L

- Hemoglobin < 8 g/dl

- Corrected reticulocyte count <1%

- Any patient with FA as determined by DEB fragility, who has life-threatening marrow
failure involving a single hematopoietic lineage

- Any patient with FA and pre-existing cytogenetic abnormality including hematopoietic
malignancy (myelodysplastic syndromes [MDS] or acute myeloid leukemia [AML]) in
remission

- DONOR: Unrelated Donors who are prospectively: Matched for human lymphocyte antigen
(HLA)-DRB1 and DQB1 alleles (must be defined by high resolution typing); only a
single allele disparity will be allowed for HLA -A, B, or C as defined by high
resolution typing

- DONOR: HLA typing will be performed at the highest level of resolution available at
the time of transplant

Exclusion Criteria:

- Evidence for hematopoietic malignancy in relapse

- Heart or lung disease that would prevent compliance with conditioning and GvHD
regimen or would severely limit the probability of survival

- Human immunodeficiency virus (HIV) seropositive patients

- Females who are pregnant or breastfeeding, or unwilling to use contraceptive
techniques during and for the 12 months following treatment

- DONOR: Donors who by DEB testing are found to have FA

- DONOR: Donors who test positive in the lymphocytotoxic crossmatch assay

- DONOR: Donors who are HIV positive

- DONOR: Donors who for other medical or psychological reasons are not suitable as
donors